secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001439222-24-000136
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M
--------------------------------------------------------------------------------

- Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.
- PYRUKYND net revenue $9.0M (+4% QoQ); 127 patients on therapy, 211 enrollment forms.
- Completed enrollment of Phase 3 RISE UP for mitapivat in SCD; topline data expected late 2025.
- Initiated Phase 2b of tebapivat in LR-MDS; FDA orphan drug designation for MDS received.
- Cash, equivalents and securities $1.7B at Sept 30, 2024, up from $806.4M at Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000136/0001439222-24-000136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922224000136/agio-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001439222-24-000136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer